205 related articles for article (PubMed ID: 20010949)
1. PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.
Munkácsy G; Abdul-Ghani R; Mihály Z; Tegze B; Tchernitsa O; Surowiak P; Schäfer R; Györffy B
Br J Cancer; 2010 Jan; 102(2):361-8. PubMed ID: 20010949
[TBL] [Abstract][Full Text] [Related]
2. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
3. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
4. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Braunstein M; Liao L; Lyttle N; Lobo N; Taylor KJ; Krzyzanowski PM; Kalatskaya I; Yao CQ; Stein LD; Boutros PC; Twelves CJ; Marcellus R; Bartlett JM; Spears M
Breast Cancer Res; 2016 Feb; 18(1):16. PubMed ID: 26852132
[TBL] [Abstract][Full Text] [Related]
6. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
7. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
8. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
[TBL] [Abstract][Full Text] [Related]
9. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
10. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
[TBL] [Abstract][Full Text] [Related]
11. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy.
Linn SC; Pinedo HM; van Ark-Otte J; van der Valk P; Hoekman K; Honkoop AH; Vermorken JB; Giaccone G
Int J Cancer; 1997 May; 71(5):787-95. PubMed ID: 9180147
[TBL] [Abstract][Full Text] [Related]
12. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
13. The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair.
Chen J; Liu JY; Dong ZZ; Zou T; Wang Z; Shen Y; Zhuo W; Li XP; Xiao D; Liu HT; Chen X; Zhou HH; Liu ZQ; Zhang JT; Yin JY
Biochem Pharmacol; 2021 Aug; 190():114616. PubMed ID: 34022189
[TBL] [Abstract][Full Text] [Related]
14. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Zhao H; Yu Z; Zhao L; He M; Ren J; Wu H; Chen Q; Yao W; Wei M
Jpn J Clin Oncol; 2016 Oct; 46(10):893-902. PubMed ID: 27432453
[TBL] [Abstract][Full Text] [Related]
15. Drug resistant breast cancer cells overexpress ETS1 gene.
Kars MD; Işeri OD; Gündüz U
Biomed Pharmacother; 2010 Sep; 64(7):458-62. PubMed ID: 20392592
[TBL] [Abstract][Full Text] [Related]
16. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance.
Yang JY; Ha SA; Yang YS; Kim JW
BMC Cancer; 2010 Jul; 10():388. PubMed ID: 20649952
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
Wang Z; Chen J; Zhong MZ; Huang J; Hu YP; Feng DY; Zhou ZJ; Luo X; Liu ZQ; Jiang WZ; Zhou WB
Cancer Chemother Pharmacol; 2017 Mar; 79(3):535-543. PubMed ID: 28243684
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
19. High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.
Zhu D; Zha X; Hu M; Tao A; Zhou H; Zhou X; Sun Y
Med Oncol; 2012 Dec; 29(5):3207-15. PubMed ID: 22544540
[TBL] [Abstract][Full Text] [Related]
20. How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment.
Gradilone A; Raimondi C; Naso G; Silvestri I; Repetto L; Palazzo A; Gianni W; Frati L; Cortesi E; Gazzaniga P
Am J Clin Oncol; 2011 Dec; 34(6):625-7. PubMed ID: 22101388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
